JAK2 and hepatocellular carcinoma: A whole-genome analysis of primary HCC [283] revealed that 9.1% of patients carry activating mutations in JAK1, and a proteogenomic characterization of virus-associated liver cancers [64] showed that JAK2 is overexpressed in a subclass of HCC.